Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report)’s stock is scheduled to reverse split on Tuesday, October 20th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 19th.
Revelation Biosciences Price Performance
Revelation Biosciences stock traded down $0.28 during mid-day trading on Friday, reaching $0.48. 632,488 shares of the company were exchanged, compared to its average volume of 40,664. The firm has a market cap of $1.93 million, a PE ratio of -0.04 and a beta of -0.07. Revelation Biosciences has a 12 month low of $0.47 and a 12 month high of $5.80. The company has a fifty day simple moving average of $0.94 and a 200-day simple moving average of $1.03.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. Sell-side analysts anticipate that Revelation Biosciences will post -5.18 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on REVB
Revelation Biosciences Company Profile
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.
The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.
Further Reading
- Five stocks we like better than Revelation Biosciences
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
